ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Former AAOA Heads Take on Allergic Rhinitis

by Matt Brown • December 1, 2006

  • Tweet
  • Email
Print-Friendly Version

TORONTO-An expert panel containing three former American Academy of Otolaryngic Allergy presidents recently provided a look at the future of allergic rhinitis, as well as a refresher on how best to treat it.

You Might Also Like

  • Sublingual Immunotherapy a Potential Treatment for Allergic Rhinitis
  • Immunotherapy Benefits for Treating Allergic Rhinitis
  • SCIT Effective for Asthma, Allergic Rhinitis
  • Upward Trend: What’s to account for the increased prevalence of allergic rhinitis?
Explore This Issue
December 2006

During the course of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) annual meeting here, AAOA past presidents J. David Osguthorpe, MD; M. Jennifer Derebery, MD; Edwyn L. Boyd, MD; and moderator Berrylin J. Ferguson, MD, presented Allergic Rhinitis: What’s True About What’s New.

According to Dr. Osguthorpe, more than 50 million Americans suffer from allergic diseases. Allergy is said to be a causative factor in up to 50% of patients presenting at otolaryngology offices. Patients with perennial or seasonal nasal congestion and sneezing, or with chronic rhinosinusitis, as well as those in whom the role of allergy is not commonly considered, such as those with hoarseness, disordered sleep, and the sequelae of eustachian tube dysfunction, all fit within this description.

In his presentation, Dr. Osguthorpe covered what is currently available for the treatment of allergies, focusing on salient aspects that physicians should consider when selecting a therapy.

Asthma affects both physical and mental status-mostly it is a ‘presenteeism’ problem, he said. Allergic rhinitis, this IgE media phenomenon, sits in the middle of a number of diseases. Asthma, of course, has the same inflammatory type of underlying process, which is true for some of the others as well.

The most common treatments for allergic rhinitis have been avoidance or environmental modification, and pharmacotherapy.

Allergic rhinitis broadly affects how one feels about getting up in the morning, Dr. Osguthorpe said. It is worst at night…is bad in the early morning…and exacerbates sleep apnea.

If you look at people who are allergic, their productivity goes down as pollen count goes up. These people just aren’t up to speed.

Figure. More than 50 million Americans suffer from allergic disease, which is a cause of up to 50% of office visits.

click for large version
Figure. More than 50 million Americans suffer from allergic disease, which is a cause of up to 50% of office visits.

Omalazumab and Zileuton

Dr. Ferguson followed Dr. Osguthorpe, talking about uses for and efficacy of omalazumab (Xolair) and zileuton (Zyflo).

Omalazumab is a human monoclonal antibody that has been designed to bind to the FC-Epsilon receptor of the immunoglobulin E molecule where IgE will bind to a receptor in a mast cell. The antigen-specific portion of the immunoglobulin is not touched at all by omalazumab, Dr. Ferguson said, so it prevents the binding of IgE to the affector cells. The dosage is based on the weight of the patient, as well as his or her IgE level.

Pages: 1 2 3 4 | Single Page

Filed Under: Allergy, Departments, Medical Education, Pediatric, Practice Focus, Rhinology, Sleep Medicine Tagged With: allergic rhinitis, allergy, Dysphonia, immunotherapy, medication, Obstructive sleep apnea, pediatrics, rhinosinusitis, steroids, treatmentIssue: December 2006

You Might Also Like:

  • Sublingual Immunotherapy a Potential Treatment for Allergic Rhinitis
  • Immunotherapy Benefits for Treating Allergic Rhinitis
  • SCIT Effective for Asthma, Allergic Rhinitis
  • Upward Trend: What’s to account for the increased prevalence of allergic rhinitis?

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Weaning Patients Off of PPIs
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.